FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
LUNESTA®
(eszopiclone) is indicated for the treatment of insomnia. In controlled outpatient
and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and
improved sleep maintenance.
The clinical trials performed in support of efficacy were up to 6 months in duration. The final
formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week
study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month
study (adults only).http://www.lunesta.com/PostedApprovedLabelingText.pdf
No comments:
Post a Comment